BIO Valuation

Bio Rad Laboratories Inc

Add to Watchlist

Advanced Chart

250.080

-2.52(-0.998%)1D

Overview
Forecast
Valuation
Earnings

BIO Relative Valuation

BIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BIO is overvalued; if below, it's undervalued.

Historical Valuation

Bio Rad Laboratories Inc (BIO) is now in the Fair zone, suggesting that its current forward PE ratio of 29.81 is considered Fairly compared with the five-year average of 37.68. The fair price of Bio Rad Laboratories Inc (BIO) is between 220.70 to 378.72 according to relative valuation methord.

Relative Value

Fair Zone

220.70-378.72

Current Price：252.60

Fair

29.73

Trailing

Forward

15.50

EV/EBITDA

Bio Rad Laboratories Inc. (BIO) has a current EV/EBITDA of 15.50. The 5-year average EV/EBITDA is 23.40. The thresholds are as follows: Strongly Undervalued below 8.93, Undervalued between 8.93 and 16.16, Fairly Valued between 30.63 and 16.16, Overvalued between 30.63 and 37.86, and Strongly Overvalued above 37.86. The current Forward EV/EBITDA of 15.50 falls within the Undervalued range.

23.09

EV/EBIT

Bio Rad Laboratories Inc. (BIO) has a current EV/EBIT of 23.09. The 5-year average EV/EBIT is 30.01. The thresholds are as follows: Strongly Undervalued below 12.66, Undervalued between 12.66 and 21.33, Fairly Valued between 38.68 and 21.33, Overvalued between 38.68 and 47.35, and Strongly Overvalued above 47.35. The current Forward EV/EBIT of 23.09 falls within the Historic Trend Line -Fairly Valued range.

2.70

Bio Rad Laboratories Inc. (BIO) has a current PS of 2.70. The 5-year average PS is 4.92. The thresholds are as follows: Strongly Undervalued below 1.59, Undervalued between 1.59 and 3.26, Fairly Valued between 6.59 and 3.26, Overvalued between 6.59 and 8.26, and Strongly Overvalued above 8.26. The current Forward PS of 2.70 falls within the Undervalued range.

0.00

P/OCF

Bio Rad Laboratories Inc. (BIO) has a current P/OCF of 0.00. The 5-year average P/OCF is 22.52. The thresholds are as follows: Strongly Undervalued below -3.26, Undervalued between -3.26 and 9.63, Fairly Valued between 35.42 and 9.63, Overvalued between 35.42 and 48.31, and Strongly Overvalued above 48.31. The current Forward P/OCF of 0.00 falls within the Undervalued range.

0.00

P/FCF

Bio Rad Laboratories Inc. (BIO) has a current P/FCF of 0.00. The 5-year average P/FCF is 29.80. The thresholds are as follows: Strongly Undervalued below -3.55, Undervalued between -3.55 and 13.12, Fairly Valued between 46.47 and 13.12, Overvalued between 46.47 and 63.14, and Strongly Overvalued above 63.14. The current Forward P/FCF of 0.00 falls within the Undervalued range.

Bio Rad Laboratories Inc (BIO) has a current Price-to-Book (P/B) ratio of 1.05. Compared to its 3-year average P/B ratio of 1.23 , the current P/B ratio is approximately -15.16% higher. Relative to its 5-year average P/B ratio of 1.42, the current P/B ratio is about -26.36% higher. Bio Rad Laboratories Inc (BIO) has a Forward Free Cash Flow (FCF) yield of approximately 5.01%. Compared to its 3-year average FCF yield of 2.25%, the current FCF yield is approximately 122.54% lower. Relative to its 5-year average FCF yield of 2.43% , the current FCF yield is about 106.03% lower.

1.05

P/B

Median3y

1.23

Median5y

1.42

5.18

FCF Yield

Median3y

2.25

Median5y

2.43

Competitors Valuation Multiple

The average P/S ratio for BIO's competitors is 2.51, providing a benchmark for relative valuation. Bio Rad Laboratories Inc Corp (BIO) exhibits a P/S ratio of 2.70, which is 7.80% above the industry average. Given its robust revenue growth of -4.16%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BIO.N

Bio Rad Laboratories Inc

Performance Decomposition

Market capitalization of BIO decreased by 26.09% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.04 to -3.28.

The secondary factor is the Revenue Growth, contributed -4.16%to the performance.

Overall, the performance of BIO in the past 1 year is driven by P/E Change. Which is more unsustainable.

-4.16%

610.82M → 585.40M

Revenue Growth

-82.61%

62.85 → 10.93

Margin Expansion

60.68%

-2.04 → -3.28

P/E Change

-26.09%